---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: TNF inhibitors"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: TNF inhibitors. Topics: Biologics guideline: recommendations for etanercept, infliximab, and adalimumab; Adalimumab: FDA-approved indication, dosage, and boxed warning; Adalimumab: Study Ps-I efficacy at week 16 and maintenance through week 52; Etanercept: FDA-approved indication, dosage, boxed warning, and Study II efficacy at 3 months; 6 further topics. 10 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/tnf-inhibitors"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: TNF inhibitors

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 TNF Inhibitors

<a id="topic-2.2.2.1.7-1"></a>

### Biologics guideline: recommendations for etanercept, infliximab, and adalimumab

> “Etanercept is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Infliximab is recommended as a monotherapy treatment option in adult patients with moderate-to-severe plaque psoriasis”
> “Infliximab is recommended to be administered at a more frequent interval (less than every 8 weeks and as frequently as every 4 weeks during the maintenance phase) and/or at a higher dose up to 10 mg/kg for better disease control in some adult patients”
> “Adalimumab is recommended as a monotherapy treatment option for adult patients with moderate-to-severe plaque psoriasis”
> “A maintenance dose of adalimumab 40 mg/wk is recommended for better disease control in some patients”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.7-2"></a>

### Adalimumab: FDA-approved indication, dosage, and boxed warning

> “HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.”
> “The recommended subcutaneous dosage of HUMIRA for adult patients with plaque psoriasis (Ps) or uveitis (UV) [see Indications and Usage (1.7, 1.9)] is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose.”
> “Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death”
> “Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.”
> “Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including HUMIRA.”

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### Adalimumab: Study Ps-I efficacy at week 16 and maintenance through week 52

| Endpoint at Week 16, n (%) | HUMIRA 40 mg every other week (N = 814) | Placebo (N = 398) |
| --- | --- | --- |
| PGA clear or minimal | “506 (62%)” | “17 (4%)” |
| PASI 75 | “578 (71%)” | “26 (7%)” |

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

> “After 52 weeks of treatment with HUMIRA, more subjects on HUMIRA maintained efficacy when compared to”
> “subjects who were re-randomized to placebo based on maintenance of PGA of “clear” or “minimal” disease (68% vs. 28%) or a PASI 75 (79% vs. 43%).”

Source: [AbbVie HUMIRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125057s425lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Etanercept: FDA-approved indication, dosage, boxed warning, and Study II efficacy at 3 months

> “Etanercept is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.”
> “Starting Dose: 50 mg twice weekly for 3 months”
> “Maintenance Dose: 50 mg once weekly”
> “Patients treated with Etanercept are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf)

| Outcome at 3 months, Study II, n (%) | Placebo (N = 204) | Etanercept 25 mg BIW (N = 204) | Etanercept 50 mg BIW (N = 203) |
| --- | --- | --- | --- |
| PASI 75 | “6 (3%)” | “66 (32%)” | “94 (46%)” |
| sPGA clear or minimal | “7 (3%)” | “75 (37%)” | “109 (54%)” |

Source: [Amgen ENBREL prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/103795s5605lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Infliximab: FDA-approved indication, intravenous dosage, boxed warning, and week 10 PASI 75

> “REMICADE is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.”
> “The recommended dosage of REMICADE in adult patients is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) Ps.”
> “Patients treated with REMICADE are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

| PASI 75 at Week 10, n (%) | Placebo | REMICADE 3 mg/kg | REMICADE 5 mg/kg |
| --- | --- | --- | --- |
| Psoriasis Study II (EXPRESS II) | “4 (2%)” | “220 (70%)” | “237 (75%)” |
| Psoriasis Study III (SPIRIT) | “3 (6%)” | “71 (72%)” | “87 (88%)” |

Source: [Janssen REMICADE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/103772s5412lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

### Certolizumab pegol: FDA-approved indication, dosage, and boxed warning

> “CIMZIA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy”
> “The recommended dose of CIMZIA for adults with moderate-to-severe plaque psoriasis is 400 mg (given as 2 subcutaneous injections of 200 mg each) every other week.”
> “For some patients (with body weight less than or equal to 90 kg), CIMZIA 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at Weeks 2 and 4, followed by 200 mg every other week can be considered”
> “Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death”

Source: [UCB CIMZIA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125160s315lbl.pdf)

<a id="topic-2.2.2.1.7-7"></a>

### Decision aid: TNF inhibitors

| Agent | Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months? | What is the likelihood of staying on this treatment for more than 1 year? |
| --- | --- | --- |
| Adalimumab | “31%” | “74–76% chance” |
| Certolizumab pegol | “24%” | “Not known at present” |
| Etanercept | “18%” | “67–73% chance” |
| Infliximab | “91%” | “54–74% chance” |

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

<a id="topic-2.2.2.1.7-8"></a>

### Network meta-analysis: infliximab and other TNF inhibitors

> “At drug‐level, using SUCRA, infliximab had a better chance of reaching PASI 90 (versus placebo: RR 49.99, 95% CI 20.83 to 119.95; SUCRA = 91.8; moderate‐certainty evidence)”
> “There was also evidence of a higher risk of SAEs for participants on infliximab compared to methotrexate (RR 2.41, 95% CI 1.04 to 5.59).”
> “Guselkumab, risankizumab, ixekizumab and bimekizumab were more effective than adalimumab.”
> “Ustekinumab, secukinumab, infliximab, ixekizumab, and tildrakizumab were more effective than etanercept.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

| Treatment | PASI 75 at 10 to 16 weeks, % (95% CrI) | PASI 90 at 10 to 16 weeks, % (95% CrI) | PASI 100 at 10 to 16 weeks, % (95% CrI) |
| --- | --- | --- | --- |
| Infliximab, 5 mg/kg | “80.4 (76.5-84.0)” | “57.4 (52.2-62.8)” | “26.5 (22.3-31.4)” |
| Certolizumab pegol, 400 mg | “71.1 (65.4-76.5)” | “45.6 (39.3-52.2)” | “17.7 (13.8-22.3)” |
| Adalimumab, 40 mg | “69.5 (66.0-72.6)” | “43.7 (40.0-47.4)” | “16.5 (14.2-19.0)” |
| Etanercept, 25 mg twice weekly/50 mg once weekly | “40.1 (35.4-45.1)” | “17.9 (14.9-21.4)” | “4.2 (3.1-5.4)” |

Source: [Armstrong et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7042876/)

<a id="topic-2.2.2.1.7-9"></a>

### Biologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline will cover the use of biologic agents in the treatment of psoriasis in adults”
> “This guideline has been developed in accordance with the American Academy of Dermatology/AAD Association Administrative Regulations for Evidence-Based Clinical Practice Guidelines (May 2014)”
> “Additionally, this guideline has been developed in collaboration with the National Psoriasis Foundation, and as part of the review process, the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Menter et al. (2019)](https://www.jaad.org/article/S0190-9622%2818%2933001-9/fulltext)

<a id="topic-2.2.2.1.7-10"></a>

### Decision aid columns: PASI 90 in the first 6 months from network meta-analyses and staying on treatment for more than 1 year from UK real-world data

> “Roughly what proportion of people are clear or nearly clear (PASI 90) in the first 6 months?”
> “What is the likelihood of staying on this treatment for more than 1 year?”
> “Anticipated absolute effect estimates were extracted for use in the updated decision aid (Table 1).”
> “figures quoted are based on anticipated absolute effects derived from network meta-analyses of biologic therapies (and methotrexate) for chronic plaque psoriasis involving licensed biologic doses only.”
> “The percentages quoted in the column on persistence on therapy after 1 year in the decision aid are derived from UK real-world data on both the mixed biologics population”
> “and the biologic-naïve population, as indicated.”
> “it may not apply to biologic choice for subsequent lines of treatment.”

Source: [Smith et al. (2024a)](https://academic.oup.com/bjd/article/190/2/270/7280929)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
